BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 11799525)

  • 1. Understanding the alloresponse: new approaches to graft-versus-host disease prevention.
    Teshima T; Ferrara JL
    Semin Hematol; 2002 Jan; 39(1):15-22. PubMed ID: 11799525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of graft-versus-host disease: role of regulatory T lymphocytes.
    Hess AD
    Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 2):13-21. PubMed ID: 16399597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Analysis of the Activation and Proliferation Kinetics and Effector Functions of Human Lymphocytes, and Antigen Presentation Capacity of Antigen-Presenting Cells in Xenogeneic Graft-Versus-Host Disease.
    Kawasaki Y; Sato K; Hayakawa H; Takayama N; Nakano H; Ito R; Mashima K; Oh I; Minakata D; Yamasaki R; Morita K; Ashizawa M; Yamamoto C; Hatano K; Fujiwara SI; Ohmine K; Muroi K; Kanda Y
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1563-1574. PubMed ID: 29678638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New developments in allotransplant immunology.
    Barrett AJ; Rezvani K; Solomon S; Dickinson AM; Wang XN; Stark G; Cullup H; Jarvis M; Middleton PG; Chao N
    Hematology Am Soc Hematol Educ Program; 2003; ():350-71. PubMed ID: 14633790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute graft-vs-host disease: pathobiology and management.
    Goker H; Haznedaroglu IC; Chao NJ
    Exp Hematol; 2001 Mar; 29(3):259-77. PubMed ID: 11274753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiology of acute graft-versus-host disease: recent advances.
    Sun Y; Tawara I; Toubai T; Reddy P
    Transl Res; 2007 Oct; 150(4):197-214. PubMed ID: 17900507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in understanding the pathogenesis of graft-versus-host disease.
    Magenau J; Runaas L; Reddy P
    Br J Haematol; 2016 Apr; 173(2):190-205. PubMed ID: 27019012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular and cytokine effectors of acute graft versus host disease.
    Ferrara JL
    Int J Hematol; 2002 Aug; 76 Suppl 1():195-8. PubMed ID: 12430853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of TIM-1 on the donor graft ameliorates graft-versus-host disease following hematopoietic cell transplantation.
    Iliopoulou BP; Hsu K; Pérez-Cruz M; Tang SW; Pang WW; Erkers T; Kambham N; Freeman GJ; Dekruyff RH; Meyer EH
    Blood Adv; 2019 Nov; 3(21):3419-3431. PubMed ID: 31714958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intervention with costimulatory pathways as a therapeutic approach for graft-versus-host disease.
    Kwon B
    Exp Mol Med; 2010 Oct; 42(10):675-83. PubMed ID: 20820112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances on cellular therapies and immune modulators for graft-versus-host disease.
    Filippini P; Rutella S
    Expert Rev Clin Immunol; 2014 Oct; 10(10):1357-74. PubMed ID: 25196777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Graft versus host disease and cytokines].
    Itoh T
    Nihon Rinsho; 2003 Sep; 61(9):1504-11. PubMed ID: 14515716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress and prospects: graft-versus-host disease.
    Mastaglio S; Stanghellini MT; Bordignon C; Bondanza A; Ciceri F; Bonini C
    Gene Ther; 2010 Nov; 17(11):1309-17. PubMed ID: 20508597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of graft-versus-host disease in SCID mice and prevention by physicochemical stressors.
    Sheng-Tanner X; McKerlie C; Spaner D
    Transplantation; 2000 Dec; 70(12):1683-93. PubMed ID: 11152097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preimplantation factor reduces graft-versus-host disease by regulating immune response and lowering oxidative stress (murine model).
    Azar Y; Shainer R; Almogi-Hazan O; Bringer R; Compton SR; Paidas MJ; Barnea ER; Or R
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):519-28. PubMed ID: 23266739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graft-versus-host disease: a complex long-term side effect of hematopoietic stem cell transplant.
    Barton-Burke M; Dwinell DM; Kafkas L; Lavalley C; Sands H; Proctor C; Johnson E
    Oncology (Williston Park); 2008 Oct; 22(11 Suppl Nurse Ed):31-45. PubMed ID: 19856578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel drugs for the prevention and treatment of acute GVHD.
    Cutler C; Antin JH
    Curr Pharm Des; 2008; 14(20):1962-73. PubMed ID: 18691107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Micronutrients in Graft-VS.-Host Disease: Immunomodulatory Effects of Vitamins A and D.
    Chen X; Mayne CG
    Front Immunol; 2018; 9():2853. PubMed ID: 30574143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.